The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Alzheimer Disease
- Inflammation
- Parkinson Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: All participants will receive two Flutriciclamide (18F-GE180) PET scans. One will be done at baseline (Y1) and one will be done approximately 12 months later (Y2).Masking: None (Open Label)Masking Description: No maskingPrimary Purpose: Diagnostic
Participation Requirements
- Age
- Between 55 years and 90 years
- Gender
- Both males and females
Description
This study will involve a cohort that is currently being established at the Cleveland Clinic Lou Ruvo Center for Brain Health. The cohort has been established under the NIH Center of Biomedical Research Excellence (COBRE) grant and involves annual collection of detailed neuropsychological testing an...
This study will involve a cohort that is currently being established at the Cleveland Clinic Lou Ruvo Center for Brain Health. The cohort has been established under the NIH Center of Biomedical Research Excellence (COBRE) grant and involves annual collection of detailed neuropsychological testing and biomarkers (blood and neuroimaging) from all participants annually. Data are filed in a registry (CNTN). Participants include healthy controls, participants with PD (with and without mild cognitive impairment (MCI)) and patients with MCI (with or without positive florbetapir scan, which demonstrates underlying AD changes likely causing the cognitive impairment) and patients with AD. For the current study, we will focus on patients with MCI with associated underlying AD or PD. Participants will undergo GE180 PET. This will occur twice, once at baseline and one year after initial testing. The approach to PET data collection and analysis will be similar to work done previously with an earlier generation ligand (Edison et al., 2008) and to other work with this tracer (Fan et al., 2016). Participants will complete ECGs and have their vitals taken prior to and immediately following injections. Briefly, the ligand will be injected, there will be a 90 minute uptake period, and scan acquisition will commence for 30 minutes, and will be collected in list mode and rebinned into 18 time frames post acquisition. The total duration of the study visit will be around 4 hours, and the participants will receive $50 compensation for the visit.
Tracking Information
- NCT #
- NCT03702816
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Aaron R Ritter, MD The Cleveland Clinic